Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells.

Abstract

Herein, we describe the synthesis, characterization, and biological properties of Pt(IV) derivatives of cisplatin with estramustine at the first axial position, which is known to disrupt the microtubule assembly and act as an androgen antagonist, and varying the second axial position using an innocent ligand (acetate or hydroxyl) to prepare dual-action and triple-action prodrugs with known inhibitors of histone deacetylase, cyclooxygenase, and pyruvate dehydrogenase kinase. We demonstrate superior antiproliferative activity at submicromolar concentrations of the prodrugs against a panel of cancer cell lines, particularly against prostate cancer cell lines. The results obtained in this study exemplify the complex mode of action of "multiaction" Pt(IV) prodrugs. Interestingly, changing the second axial ligand in the Pt-estramustine complex has a significant effect on the mode of action, suggesting that all three components of the Pt(IV) prodrugs (platinum moiety and axial ligands) contribute to the killing of cells and not just one dominant component.

• Authors: Subhendu Karmakar, Hana Kostrhunova, Tereza Ctvrtlikova, Vojtech Novohradsky, Dan Gibson, Viktor Brabec
• Journal: Journal of medicinal chemistry (J Med Chem) Vol. 63 Issue 22 Pg. 13861-13877 (11 25 2020) ISSN: 1520-4804 [Electronic] United States
• PMID: 33175515 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Prodrugs
• Estramustine
• Cisplatin

Topics

• Antineoplastic Agents (chemistry, pharmacology)
• Cisplatin (chemistry)
• Drug Screening Assays, Antitumor
• Estramustine (chemistry)
• Humans
• Male
• Prodrugs (chemistry, pharmacology)
• Prostatic Neoplasms (drug therapy, pathology)
• Tumor Cells, Cultured